SmartinBio

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
Our company was found in 2019 to develop first-in-class drugs targeting mitochondrial chaperone. Our drugs reprogram cellular metabolism to fix abnormal angiogenesis and to inhibit dysregulated cell growth. We have repositioned drugs and drug candidates for diabetic retinopathy, acute myeloid leukemia, and solid tumors.
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2019
Main Therapeutic Focus:
Lead Product in Development:
SMX and its derivatives
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
SmartinBio